Wells Fargo added that Bausch + Lomb (NYSE:BLCO) is unlikely to have a quick fix for the recall, as it could hurt the company’s market share and weigh on the timing of upcoming enVista launches ...

Investing.com -- Wells Fargo downgraded Bausch + Lomb Corp to Equal Weight from Overweight on uncertainty from the voluntary recall of its enVista intraocular lenses (IOLs), which is expected to ...

Wells Fargo downgraded Bausch + Lomb (BLCO) to Equal Weight from Overweight with a price target of $15, down from $24. The company’s announced enVista recall due to an increased number of ...

Wells Fargo downgraded Bausch + Lomb (BLCO) to Equal Weight from Overweight with a price target of $15, down from $24. Published first on TheFly – the ultimate source for real-time, market ...

Bausch + Lomb (NYSE:BLCO – Get Free Report)‘s stock had its “equal weight” rating reissued by research analysts at Wells Fargo & Company in a research note issued to investors on Friday ...

Bausch + Lomb (NYSE:BLCO) continued to trade lower on Friday as Wells Fargo downgraded the Canadian eyecare firm in reaction to a voluntary recall of several brands of its enVista line of ...

Investing.com -- Wells Fargo downgraded Bausch + Lomb Corp to Equal Weight from Overweight on uncertainty from the voluntary recall of its enVista intraocular lenses (IOLs), which is expected to weigh ...